Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

(2010) Helena R. Chang   CANCER

Current and emerging biomarkers in breast cancer: prognosis and prediction

(2010) Marion T Weigel et al.   ENDOCRINE-RELATED CANCER

Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage

(2010) Chee Wee Ong et al.   HISTOPATHOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

(2009) Marieke E. Straver et al.   BREAST CANCER RESEARCH AND TREATMENT

Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients

(2009) J G H van Nes et al.   BRITISH JOURNAL OF CANCER

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

(2009) T. Tanei et al.   CLINICAL CANCER RESEARCH

Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide

(2009) Seung Jin Kim et al.   ONCOLOGY

Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients

(2008) R. Stuart-Harris et al.   BREAST